[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals Inc (XENE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Xenon Pharmaceuticals Inc 200-3650 GILMORE WAY BURNABY A1 V5G 4W8 CAN

www.xenon-pharma.com Employees: 370 P: 604-484-3300 F: 604-484-3450

Sector:

Medical

Description:

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.

Key Statistics

Overview:

Market Capitalization, $K 5,338,559
Enterprise Value, $K 5,139,399
Shares Outstanding, K 96,643
Float, K 92,710
% Float 95.93%
Short Interest, K 4,851
Short Float 5.83%
Days to Cover 3.54
Short Volume Ratio 0.48
% of Insider Shareholders 4.07%
% of Institutional Shareholders 95.45%

Financials:

Annual Sales, $ 7,500 K
Annual Net Income, $ -345,910 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -105,260 K
EBIT, $ -373,080 K
EBITDA, $ -370,540 K

Growth:

1-Year Return 44.61%
3-Year Return 37.14%
5-Year Return 201.53%
5-Year Revenue Growth -76.69%
5-Year Earnings Growth -438.27%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.31 on 02/26/26
Next Earnings Date 05/11/26 [--]
Earnings Per Share ttm -4.36
EPS Growth vs. Prev Qtr -13.91%
EPS Growth vs. Prev Year -55.95%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

XENE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -55.81%
Return-on-Assets % -52.04%
Profit Margin % -4,612.13%
Debt/Equity 0.00
Price/Sales 714.00
Price/Cash Flow N/A
Price/Book 7.36
Book Value/Share 7.53
Interest Coverage -3.33
60-Month Beta 0.74
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.